The latest announcement is out from Immuneering (IMRX).
Immuneering Corporation has enhanced its leadership by appointing Dr. Thomas J. Schall as a Class I Director to its Board, with standard compensation and indemnification agreements in place. On the development front, the company has begun dosing the first patient in a Phase 2a trial for IMM-1-104, targeting advanced RAS-mutant solid tumors, aiming to enroll 150 patients across multiple U.S. sites. Additionally, promising early results from the ongoing Phase 1 trial indicate good tolerability, substantial inhibition of key cancer markers, and no concerning safety issues, showing initial signs of the drug’s effectiveness in shrinking tumors. Further details on the trial’s progress are slated for presentation at an upcoming medical meeting.
For a thorough assessment of IMRX stock, go to TipRanks’ Stock Analysis page.
